首页> 美国卫生研究院文献>Oncology Letters >Upregulation of seladin-1 and nestin expression in bone marrow mesenchymal stem cell transplantation via the ERK1/2 and PI3K/Akt signaling pathways in an Alzheimers disease model
【2h】

Upregulation of seladin-1 and nestin expression in bone marrow mesenchymal stem cell transplantation via the ERK1/2 and PI3K/Akt signaling pathways in an Alzheimers disease model

机译:在阿尔茨海默病模型中通过ERK1 / 2和PI3K / Akt信号通路在骨髓间充质干细胞移植中seladin-1和nestin表达上调

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to determine the roles of bone marrow mesenchymal stem cell (BM-MSC) transplantation in a model of Alzheimer's disease (AD) and determine the underlying mechanism. The expression of selective Alzheimer's disease indicator-1 (Seladin-1) and nestin was detected using reverse transcription-quantitative polymerase chain reaction and western blot analysis. The phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK)1/2 inhibitors, and PD98059, were employed to evaluate the molecular mechanism. The results indicated that the mRNA and protein expression of Seladin-1 and nestin was lower in the AD group when compared with the control group. BM-MSC transplantation reversed this decrease in expression, potentially by increasing the protein expression of phosphorylated (p)-protein kinase B (Akt) and p-ERK1/2. In addition, (the PI3K inhibitor) and/or PD98059 (the ERK1/2 inhibitor) blocked the enhancement of BM-MSC transplantation on the expression of Seladin-1 and nestin in the hippocampus. These results indicated that BM-MSC transplantation enhanced Seladin-1 and nestin expression potentially via a mechanism associated with the activation of the PI3K/Akt and ERK1/2 signaling pathways. The present study offers preliminary evidence that treatment with BM-MSCs may represent a potential therapeutic approach against brain lesions in AD.
机译:本研究的目的是确定骨髓间充质干细胞(BM-MSC)移植在阿尔茨海默病(AD)模型中的作用并确定其潜在机制。使用逆转录-定量聚合酶链反应和蛋白质印迹分析检测选择性阿尔茨海默病指示剂1(Seladin-1)和巢蛋白的表达。磷酸肌醇3-激酶(PI3K)和细胞外信号调节激酶(ERK)1/2抑制剂和PD98059用于评估分子机制。结果表明,AD组Seladin-1和nestin的mRNA和蛋白表达均低于对照组。 BM-MSC移植可以通过增加磷酸化(p)-蛋白激酶B(Akt)和p-ERK1 / 2的蛋白表达来逆转这种表达降低。此外,(PI3K抑制剂)和/或PD98059(ERK1 / 2抑制剂)阻止了BM-MSC移植对海马中Seladin-1和nestin表达的增强。这些结果表明,BM-MSC移植可能通过与PI3K / Akt和ERK1 / 2信号通路激活相关的机制增强Seladin-1和nestin表达。本研究提供了初步的证据表明,用BM-MSC进行治疗可能代表了一种针对AD脑损伤的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号